N-[[4-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]methyl]propan-2-amine;5,6,7,8-tetrahydroquinoline
C25H36N6 — CID 143191657
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[[4-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]methyl]propan-2-amine;5,6,7,8-tetrahydroquinoline
N-[[4-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]methyl]propan-2-amine;5,6,7,8-tetrahydroquinoline (PubChem CID 143191657) has the molecular formula C25H36N6 and a molecular weight of 420.61 g/mol. Its IUPAC name is N-[[4-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]methyl]propan-2-amine;5,6,7,8-tetrahydroquinoline.
Molecular Properties
| Compound Name | N-[[4-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]methyl]propan-2-amine;5,6,7,8-tetrahydroquinoline |
|---|---|
| PubChem CID | 143191657 |
| Molecular Formula | C25H36N6 |
| Molecular Weight | 420.61 g/mol |
| Exact Mass | 420.30 |
| IUPAC Name | N-[[4-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]methyl]propan-2-amine;5,6,7,8-tetrahydroquinoline |
| SMILES | CC(C)NCc1nc2c(N3CCN(C)CC3)cccc2[nH]1.c1cnc2c(c1)CCCC2 |
| InChI | InChI=1S/C16H25N5.C9H11N/c1-12(2)17-11-15-18-13-5-4-6-14(16(13)19-15)21-9-7-20(3)8-10-21;1-2-6-9-8(4-1)5-3-7-10-9/h4-6,12,17H,7-11H2,1-3H3,(H,18,19);3,5,7H,1-2,4,6H2 |
| InChIKey | PJRATQJJKBJUFR-UHFFFAOYSA-N |
| XLogP | 3.77 |
| TPSA | 60.08 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 420.61 |
| LogP ≤ 5 | 3.77 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 143191657 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.